 efficacy tolerability CV dopaminergic drug macroprolactinoma patients prolactinoma patients effect CV patients macroprolactinomas patients PRL-secreting tumors previous intolerance small doses serum insulin-like growth factor-I IGF-I levels CV therapy macroprolactinoma patients yr mg CV PRL levels patients transient side-effects nausea dizziness fatigue patients PRL-secreting tumors bromocriptine intolerant CV mg PRL levels patients transient side-effects nausea fatigue and/or tachycardia None patients close correlation pretreatment PRL levels tumor size cubic millimeters decrease pituitary tumor size weeks CV therapy decrease PRL levels patients hypopituitarism IGF-I levels CV therapy untreated patients macroprolactinoma normal CV potent dopaminergic drug PRL secretion induces tumor shrinkage doses study mild transient side-effects minority patients hyperprolactinemic patients intolerance therapy